Drug development for neurodegenerative diseases is struggling with one of its most intractable barriers: the slow, variable, and subjective nature of clinical endpoints Traditional assessment scales, whether in Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), or multiple sclerosis (MS), and Alzheimer disease (AD), often miss subtle or early changes, leading to long, costly trials that delay patient access to urgently needed therapies. These limitations force pharma companies to recruit larger cohorts, extend study durations, and absorb high attrition risk, resulting in increased trials’ costs.

A promising solution may be hiding in plain sight. Eye movements offer a fast, objective, and highly sensitive way to capture changes throughout CNS disease progression. With t

See Full Page